CMPX - Compass Therapeutics, Inc. News

Sectors

CMPX

Compass Therapeutics, Inc.

2.26

1 x 2.25

1 x 2.27

bid

ask

0.11

4.64%

23 @ 04:00 PM

2.25 -0.01 (0.44%)

Ytd	-57.91%
1y	-27.10%

2.23

day range

2.37

1.61

52 week range

6.88

Open	2.37	Prev Close	2.37	Low	2.23	High	2.37	Mkt Cap	407.00M
Vol	2.26M	Avg Vol	3.60M	EPS	-0.40	P/E	-5.65	Forward P/E	-10.86
Beta	1.30	Short Ratio	12.39	Inst. Own	88.00%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	05-05	50-d Avg	2.10	200-d Avg	4.12	1yr Est	13.64

CMPX News

globenewswire.com

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data fo

benzinga.com

Compass Therapeutics Abstract Accepted For Oral Presentation At Upcoming European Society For Medica

Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical compa

globenewswire.com

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stag

seekingalpha.com

Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity

Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff.

seekingalpha.com

Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

marketbeat.com

Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win

Compass Therapeutics NASDAQ: CMPX Chief Executive Officer Tom Schuetz said the company is preparing

globenewswire.com

Compass Therapeutics to Participate in Upcoming June Investor Events

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage

globenewswire.com

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanc

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage

gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutic

prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutic

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutic

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest

gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutic

prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutic

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutic

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest

globenewswire.com

Compass Therapeutics to Participate in Upcoming May Investor Events

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage

prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutic

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors o

globenewswire.com

Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

As recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel

prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutic

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

seekingalpha.com

Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 S

benzinga.com

12 Health Care Stocks Moving In Monday's Intraday Session

globenewswire.com

Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Infor

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims

benzinga.com

Earnings Scheduled For August 11, 2025

benzinga.com

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Wednesday's After-Market Session